The sixth report of the ESHRE PGD Consortium is presented, relating to cycles collected for the calendar year 2003 and follow-up of the pregnancies and babies born up to October 2004. Since the beginning of the data collections, there has been a steady rise in the number of cycles, pregnancies and babies reported. For this report, 50 centres participated, reporting on 2984 cycles, 501 pregnancies and 373 babies born. Five hundred and twenty-nine cycles were reported for chromosomal abnormalities, 516 cycles were reported for monogenic diseases, 137 cycles were reported for sexing for X-linked diseases, 1722 cycles were reported for preimplantation genetic screening (PGS) and 80 cycles were reported for social sexing. Data VI is compared to the cumulative data for data collections I-V.
Introduction
Since 1999, the ESHRE PGD Consortium has reported on a regular basis on the current practice of PGD, as reported by their members (ESHRE PGD Consortium Steering Committee, 1999 Committee, , 2000 Committee, , 2002 Sermon et al., 2005; Harper et al., 2006) . The data analysed previously included referral and clinical data on the patients consulting for PGD, the cycles they underwent, the pregnancies that ensued from these cycles and the babies born.
Because the analysis of the referral and clinical data was biased by several factors, e.g. the underreporting of couples who did not come through for PGD, this analysis is left out for the current report.
Materials and methods
Data were collected using a FileMaker Pro 5 database consisting of files for cycle records, frozen cycle records, pregnancies and babies. A first general round of correction was carried out, requesting corrections from participating centres, followed by a more in-depth correction by expert co-authors. Cycles with insufficient data, e.g. with no cycle or patient identification or no clear indication, cycles from the wrong time period, or reported after the closure of the collection period, were eliminated from the calculations.
Results
The membership has increased steadily, and while in the first report data on sixteen centres were included (ESHRE PGD Consortium Committee, 1999), that figure has now increased to 50. This has also led to a steady increase in the number of cycles reported, from 392 in the first report to 3929 in the current report.
The results are represented in tables according to a now set layout. Accompanying text is limited to the minimum, and seven tables are only available in an electronic version: Supplementary Table IIc with the list of abnormal karyotypes, Supplementary Table IIIc with the list of X-linked diseases for which sexing was carried out, Supplementary Table IVc with the list of monogenic diseases for which PGD was carried out, Supplementary Tables VIIIa (data I-V) and VIIIb (data VI) with the complications of pregnancy and Supplementary Tables XIIa (data I-V) and XIIb (data VI) with the congenital malformations and the neonatal complications.
An overview of all cycles collected previously in data collections I-V can be found in Table Ia , whereas an overview of the current data collection can be found in Table Ib .
PGD cycles for chromosomal abnormalities
Tables IIa and IIb summarize the 1207 and 529 cycles collected for data collection I-V and VI, respectively. Overall, there was very little difference between the two data collections. Reciprocal translocation was the most frequent class of chromosome aberration; ICSI was the predominant mode of fertilization; acid Tyrodes with cleavage aspiration was the predominant sampling method. A global average of 14.3 and 14.0 cumulus oocyte complexes (COCs) per oocyte retrieval (OR) cycle was collected for the I-V and VI data collections, respectively; the fertilization rate (74 and 70%), the proportion of successfully biopsied embryos which gave a diagnosis (91 and 92%), the proportion of successfully biopsied embryos with a transferable result (25 and 25%) and the clinical pregnancy rate per OR (15 and 14%) were similar.
The relatively low pregnancy rates are likely to reflect that the low proportion of embryos with a transferable result limits the choice of embryo for transfer (24% of embryos biopsied for all classes of chromosome aberration and only 17% of embryos for reciprocal translocation cycles in particular for the data collection VI). Table IIIa summarizes data I-V and Table IIIb summarizes the data from collection VI for sexing only for X-linked disease using the PCR or fluorescent in-situ hybridization (FISH). IVF  369  511  113  993  ICSI  2444  2501  128  5073  IVF + ICSI  3  13  0  16  Frozen  9  4  5  18  Frozen and ICSI  14  5  5  24  Frozen and IVF  0  0  1  1  Cancelled ICSI  3  0  0  3  Unknown  18  44  0  62  Unknown and frozen  2  0  2  4  Cancelled after OR  161  128  14  303  Cycles to PGS/PGD  2701  2950  240  5891  FISH  1577  2950  143  4670  PCR  1124  0  97  1221  Zona breaching  AT drilling  1703  1808  19  3530  Laser drilling  856  1000  112  1968  Mechanical  128  77  109  314  Unknown  14  65  0  79  Biopsy method  Polar body biopsy  25 1  178 1  0  2 0 3 1  Cleavage aspiration  2576 1  2481 1  130  5187 1  Cleavage extrusion  85  224  110  419  Cleavage flow displacement  2  16  0  18  Unknown  16  52  0  68  Embryology  COC  38955  38561  3291  80807  Inseminated  33353  32839  2772  68964  Fertilized  24239  23323  1891  49453  Biopsied  18368  17549  1589  37506  Successfully biopsied  17998  17232  1505  36735  Diagnosed  15833  15036  1367  32236  Transferable  6085  5353  652  12090  Transferred  4380  4460  449  9289  Frozen  793  687  149  1629  Clinical outcome  Cycles to ET  2173  2188  192  4553  hCG positive  656  702  78  1436  Positive heart beat  514  534  59 A total number of 137 cycles were collected in this group, with 134 cycles using FISH and three cycles using PCR. The biopsy was successful in 98% of embryos biopsied and 92% of the embryos successfully biopsied were diagnosed. A transfer was achieved in 76% of the cycles with an average of 1.7 embryos transferred in each cycle. The overall clinical pregnancy rate was 22% per OR and 30% per embryo transfer (ET) procedure, with an implantation rate of 21%.
PGD cycles for sexing for X-linked diseases
Supplementary Table IIIc summarizes the list of 36 indications. The most common indication was Duchenne muscular dystrophy (n = 33; 25%), haemophilia (n = 25; 19%), retinitis pigmentosa (n = 6), adrenoleukodystophy (n = 6), Alport syndrome (n = 5) and non-fragile X, X-linked mental retardation (n = 5).
Overall, these data are quite unremarkable and very comparable to previous data collections (I-V). In contrast to other indication groups, the number of cycles for sexing for X-linked diseases remains stable.
PGD for monogenic diseases
Amongst PGD cycles initiated for single-gene disorders between January and December 2003, the most common autosomal recessive diseases were cystic fibrosis, β-thalassemia (with or without HLA typing), spinal muscular atrophy and sickle cell anaemia. The most common autosomal dominant diseases were Huntington disease, myotonic dystrophy, adenomatous polyposis coli and Marfans syndrom. The most common specific diagnosis of X-linked diseases was for Duchenne and ART, assisted reproduction technique; AT, acid Tyrode's; COC, cumulus oocyte complexes; FISH, fluorescent in-situ hybridization; OR, oocyte retrieval; PGS, preimplantation genetic screening. PGD column includes PGD for chromosome abnormalities, sexing for X linked disease and PGD for monogenic disorders 1 Includes two cycles with PGD on frozen embryos only. These cycles were not counted in the cycles with OR. PGD  PGS  PGD-SS  Total   Total number of cycles  1182  1722  80  2984  Number infertile  501  1473  1  1975  Female age  33  37  38  35  Cycles cancelled before OR  133  9  1  143  Cycles to OR  1047 1  1713  79  2839  Cycles cancelled before ART  2  0  0  2  ART method  IVF  97  124  5  226  ICSI  902  1558  71  2531  IVF + ICSI  17 Becker muscular dystrophy, fragile X and haemophilia. PGD cycles for an additional 47 monogenic diseases were initiated in 104 cycles, included under 'other' in Table IVb , listed in Supplementary Table IVc . An average of 13.8 oocytes were collected per OR, biopsy was successful in 98% of embryos, diagnosis was achieved in 86% of embryos successfully biopsied, and 75% of cycles to OR had an ET, with 667 embryos transferred. Overall, 20% of cycles that reached the stage of OR resulted in a clinical pregnancy (or 27% clinical pregnancy rate per ET).
Indication
As recommended (Thornhill et al., 2005) , 434 cycles had ICSI and 11 cycles had ICSI and frozen (two of which were just frozen embryos). Two cycles were noted as IVF and frozen and 3 cycles as IVF and ICSI. Laser drilling was used for zona breaching in 64% of biopsy cycles, with cleavage aspiration accounting for 85% of biopsy procedures. In addition 17 cycles (4%) used trophectoderm biopsy in blastocysts; representing the first time, blastocyst biopsy has been reported to ESHRE for clinical PGD cycles.
Overall, the number of PGD cycles performed for monogenic disorders between January and December 2003 represents the largest number performed in a single year so far. The assisted reproduction techniques (ART) and embryology procedures applied reflect accumulated experience and expertise, along with technological developments, e.g. laser drilling and blastocyst biopsy.
With respect to the progress and outcome of cycles, including the embryology, rates of diagnosis and clinical outcome such as clinical pregnancy and embryo implantation rates, there are no apparent changes compared to previous data collections (Table IVa and Supplementary Table IVc ).
Preimplantation genetic screening
The cumulative data for preimplantation genetic screening (PGS) from collections I-V are summarized in Table Va . Table Vb summarizes the data from collection VI. It is clear that the number of PGS cycles continues to rise. In last year's data collection (data COC  2668  2272  4490  4445  1657  1106  16638  Inseminated  2262  1885  3832  3860  1343  982  14164  Fertilized  1573  1404  2865  2945  965  679  10431  Biopsied  1029  1142  2290  2425  696  533  8115  Successfully biopsied  1003  1120  2248  2387  683  517  7958  Diagnosed  850  1013  2050  2212  614  472  7211  Transferable  328  300  450  470  289  171  2008  Transferred  258  244  385  403  202  128  1620  Frozen  14  22  11  17  19  14  97  Clinical outcome  Cycles to ET  135  125  193  204  102  60  819  hCG positive  40  41  50  49  31  18  229  Positive heart beat  34  32  36  37  20  16  175  Clinical pregnancy (Harper et al., 2006) , whereas this year 1722 cycles were reported, which represents a 42% increase. The largest increase was seen in cycles for repeated implantation failures (RIF) (275-462; 68% increase) and in cycles for severe male factor (101-188; 86% increase). As for the previous data collections, there was an underreporting of cycles that were cancelled before OR. Only 9 of 1722 cycles were reported to be cancelled, whereas in general cancellation rates are in the range of 5-10%. As a result, the outcome of PGS can only be presented as clinical pregnancy rate per OR or per ET but not per cycle started. This may partly be explained by the fact that many reporting centres only receive the blastomeres for analysis, while the IVF cycle is done elsewhere, making accurate reporting of cycles more difficult and as a result incomplete.
For data collection VI, 9496 embryos were biopsied, and a result was obtained for 8795 embryos (93% of biopsied embryos). Of 3193 embryos diagnosed as transferable (34% of all biopsied embryos), 2277 were transferred and 454 were frozen. In total, 384 embryos implanted (17% implantation rate).
The overall clinical pregnancy rate was 18% per OR and 24% per ET. These results are similar to the results from collection V (16 and 23% clinical pregnancy rate per OR and ET, respectively). The clinical pregnancy rate per OR ranged from 9% for advanced maternal age (AMA) + recurrent miscarriage to 31% for 'other indications'. These differences in results between various indications reflect at least in part differences in patient and cycle specific data. For instance, in women treated with PGS for AMA (12% clinical pregnancy rate per OR), the mean age was 41 years and the average number of oocytes obtained per OR was 9.8. For couples treated with PGS for severe male factor (28% clinical pregnancy rate per OR), the mean age was only 33 years and the average number of oocytes obtained was 14.6. Total cycles  91  60  143  159  32  44  529  Number infertile  79  34  103  95  28  24  363  Female age  33  33  34  34  33  33  33  Cycles cancelled before OR  8  9  15  17  0  9  58  Cycles to OR  83  51  128  142  32  35  471  Cancelled before ART  0  0  0  0  0  1  1  ART method  IVF  2  4  10  40  4  4  64  ICSI  78  44  106  94  28  28  378  IVF + ICSI  1  1  2  5  0  1 (Table VIa) .
PGD cycles for social sexing

Pregnancies and babies
The cumulative data for collection I-V is summarized in Tables VIIa-XIIa. It is becoming apparent that PGD babies are very comparable to ICSI babies in every respect, e.g. complications of pregnancy, characteristics at birth and major and minor malformations.
Of the 666 cycles ending in a positive hCG, no pregnancy was reported in 186 cases: for 89 pregnancies, no information was given by the centres. For 89 further cycles with a positive hCG, no pregnancy was reported because there was no positive heartbeat (these are not the same as the 46 subclinical pregnancies that were reported, Table VIIb) . A further eight cycles ending in a positive hCG were lost to follow-up. No cycle was reported for 21 pregnancies. This results in the reporting of 501 pregnancies. Five hundred and one pregnancies ended in 373 reported deliveries, leading to the birth of 453 babies (295 singletons, 152 twins and 6 triplets). Two pregnancies were Table IIIa . Sexing only for X-linked disease using PCR or FISH, data collection I-V ART, assisted reproduction technique; AT, acid Tyrode's; COC, cumulus oocyte complexes; FISH, fluorescent in-situ hybridization; OR, oocyte retrieval. 1 27 embryos from two cycles frozen before biopsy due to hyperstimulation. 2 20 embryos frozen before biopsy. 3 11 cycles with embryos frozen without biopsy or after failed diagnosis included. 4 Thirteen cycles with embryos frozen without biopsy or failed diagnosis included. 5 Twenty four cycles with embryos frozen without biopsy or after failed diagnosis included. 6 11 embryos transferred removed from calculations dues to lack of information regarding the number of FHB in pregnancies resulting from the transfer of those embryos. terminated because of an encephalocele and spina bifida diagnosed on ultrasound. Sixty-nine of 403 ongoing pregnancies (17%) presented with complications, mainly bleeding and emesis. One hundred and five of 373 pregnancies were delivered prematurely (28%), 48 singleton pregnancies (16%), 55 twin pregnancies (72%) and 2 triplet pregnancies (100%). As before, all parameters e.g. weight, length and head circumference were comparable to those of ICSI babies (Bonduelle et al., 2002) and previous PGD Consortium reports (Harper et al., 2006) . Seventeen babies were born with malformations (4%), eleven of which were major malformations.
Two hundred and fifty-seven of the 564 fetal sacs were tested prenatally (46%), whereas 203 of 564 fetal sacs were tested post-natally (36%). These figures cannot be added, as some fetal sacs were tested both prenatally and post-natally. Abnormalities were found in 13 instances: four prenatally, two of which ended in a termination of pregnancy (TOP) and nine post-natally. Eight abnormalities were found in miscarriage material, whereas one abnormal karyotype was found at birth.
Of the misdiagnosis: a trisomy 13 was found in miscarriage material after PGD for 45,XY,der(13;14)(q10;q10). Although difficult to trace, the centre where this misdiagnosis occurred seem to Table IVa . Cycles performed for single gene disorders using PCR, data collection I-V ACH, achondroplasia; AP, amyloid polyneuropathy; ART, assisted reproduction technique; AT, acid Tyrode's; CF, cystic fibrosis (various mutations); CMT, Charcot-Marie-Tooth disease; COC, cumulus oocyte complex; DM1, myotonic dystrophy type 1; DMD, Duchenne muscular dystrophy (specific); EB, epidermolysis bullosa; FRAXA, fragile-X syndrome; Haem, haemophilia; HD, Huntington's Disease; MS, Marfan's syndrome; OR, oocyte retrieval; SC, sickle-cell anaemia; SMA, spinal muscular atrophy; β-thal, β -thalassaemia. 1 Includes nine HD with exclusion. 2 Three cycles had both polar body biopsy and cleavage stage biopsy. 3 Two cycles for two indications: cystic fibrosis and fragile X syndrome; cystic fibrosis and social sexing. 4 Eight cycles with missing data. 5 Includes three cycles of β -thalassaemia with HLA typing. 6 Includes two cycles for sickle cell and β -thalassaemia. 7 Includes one cycle for X-linked dominant inheritance. 8 Total cycles  324  144 5  93  27  9  203  146  10  22  7  10  43  51  18  137 1244  Number infertile  107  69  9  6  0  20  14  7  0  0  0  5  14  0  16  267  Female age  33  33  67  34  31  33  33  28  33  34  32  32  36  29  33  33  Cycles cancelled before OR  36  15  6  2  0  20  16  0  1  0  0  4  3  0  11  114  Cycles to OR  288  129  87  25  9  183  130  10  21  7  10  39  48  18  126 1130  Cycles cancelled before ART  0  0  0  0  0  3  0  0  0  0  0  0  0  0  0  3   ART method  IVF  15  0  1  0  0  1  0  1  0  0  0  3  2  6  2  31  ICSI  268  128  81  25  9  176  127  9  21  7 32  79  333  276  134  1154  8960  Biopsied  1778  684  501 137  87  974  738  78  100  24  64  263  193  81  828  6530  Successfully biopsied  1759  673  498 135  87  962  723  78  99  24  63  258  192  80  819  6450  Diagnosed  1492  544  419 116  66  812  608  61  83  20  58  221  163  48  701  5412  Transferable  902  293  264  72  37  355  264  32  35  10  36  152  67  33  342  2894  Transferred  500  230  172  52  23  266  167  25  21  9  25  79  46  30  231  1876  Frozen  173  40  17  33  0  22  37  0  5  0  4  40  10  4  76  461   Clinical outcome  Cycles to ET  239  108  77  22  8  138  102  9  11  6  10  33  29  13  104  909  hCG positive  75  42  23  6  3  37  24  3  5  0  2  11  9  6  38  284  Postive heart beat  59  34  19  4  1  29  18  1  5  0  2 β-thal, β-thalassaemia. 1 Two cycles had both aneuploidy screening and PGD for FRAXA. 2 Two cycles were on frozen-thawed embryos only, so they were not counted as cycles with an OR, but were counted as cycles going to PGD. Indication attribute it to a human error without discarding a FISH error or embryonic mosaicism, because the diagnosis was established on one cell. The trisomy 16 found in miscarriage material after PGS for AMA and RIF occurred after first polar body biopsy only, in which clearly two signals for chromosome 16 had been found. The second trisomy 16 found in miscarriage material occurred after PGS at the cleavage stage. Re-probing of the fixed blastomere clearly showed two signals for chromosome 16. Although a FISH error seems unlikely, the cause of this error (mosaicism of the embryo, human error) cannot be traced anymore.
Seventeen misdiagnoses have been reported in six reports, ten for PCR and seven for FISH. Except for one misdiagnosis for a reciprocal translocation where an inappropriate probe scheme was used (Sermon et al., 2005 ; Mackie Ogilvie and Scriven, 2004; Kyu Lim et al., 2004) , the reason for the misdiagnoses is difficult to establish.
Discussion
This sixth report of the ESHRE PGD Consortium reports on an ever-increasing number of cycles, pregnancies and babies, ART, assisted reproduction technique; AT, acid Tyrode's; COC, cumulus oocyte complexes; ET, embryo transfer; OR, oocyte retrieval. Other-includes data with two indications. 1 These data were not extracted from I-IV. 2 These data were not extracted from I-III. 3 One cycle had cleavage stage biopsy and polar body biopsy. 4 Several cycles had incomplete results. 5 Several cycles from one centre had no information on the number of embryos diagnosed, number embryos diagnosed as transferable, but patients did have embryos transferred. In these cases, undiagnosed or abnormal embryos were transferred. Total cycles  1043  43  129  483  917  166  67  263  3111  Number infertile  990  36  114  419  893  166  63  213  2894  Female age  40  40  40  36  36  32  33  35  36  Cycles cancelled  before OR   3  2  0  1 0  1 3  2  1  2  3 3   Cycles to OR  1040  41  129  473  904  164  66  261  3078   ART method  IVF  197  9  33  52  143  2  16  59  511  ICSI  835  32  94  417  725  161  50  187  2501  IVF + ICSI  2  0  1  2  7  0  0  1 Embryology  COC  10907  391  1311  6663  12600  2476  836  3377  38561  Inseminated  9466  324  1116  5586  10801  1976  745  2825  32839  Fertilized  6742  192  795  3979  7738  1315  547  2015  23323  Biopsied  5406  209  739  3017  5227  971  435  1545  17549  Successfully biopsied  5325  208  733  2921  5155  958  413  1519  17232  Diagnosed  4509 5  199  710  2455 from a still increasing number of participating centres. For this report, the referrals are not included, because it was felt from previous reports that the data were biased and incomplete. Indeed, only few centres reported all referrals, i.e. referrals for patients who did not come through for PGD because either it was technically impossible to help them, or for ethical reasons, or reasons related to IVF e.g. AMA.
An interesting feature is the relative increase in the number of PGS cycles. This reflects the fact that many IVF laboratories offer PGS, and PGS only, as an additional method to select the best embryo for transfer. The ESHRE PGD Consortium Steering Committee would like to emphasize that they feel that there is a need for large randomized controlled trials to investigate the (cost-)effectiveness of PGS for well-defined indications. Currently, there are insufficient data that demonstrate that PGS is indeed a cost-effective alternative for standard IVF (Staessen et al., 2004; Twisk et al., 2006) . PGD for monogenic diseases and chromosomal abnormalities have also been steadily increasing, whereas sexing (both for X-linked diseases and for social sexing) remains stable. For the sexing for X-linked diseases, this reflects the fact that more and more specific PGD at the DNA level is offered. For social sexing, only two centres offer it, and this has remained the same for the last three reports. To be able to offer PGD for monogenic diseases or chromosomal abnormalities, a close collaboration between an IVF centre and a genetic laboratory is mandatory. The higher technical expertise needed for this type of diagnosis explains why less centres are able to offer it.
It becomes obvious that at birth PGD babies have characteristics that are comparable to those of ICSI babies. No pregnancy complication or malformation at birth is particularly occurring in the PGD population. The characteristics of the babies at birth are also comparable, and the main complication remains multiple pregnancies leading to morbidity and mortality in PGD offspring.
The Total cycles  124  22  103  5  254  Number infertile  18  6  16  1  41  Female age  35  38  35  35  35  Cycles cancelled before OR  0  0  0  0  0  Cycles to OR  124  22  103  5 1  254 1  ART method  IVF  104  1  5  3  113  ICSI  17  21  88  2  128  Frozen  3  0  2  0  5  Frozen and IVF  0 The ESHRE PGD Consortium also aims at constantly improving the data collection and its processing. A major reorganization of the database is planned, and better follow-up of data submission is now reassured by a permanent staff member at ESHRE. Quality assessment of captured FISH images is planned, as well as retrospective analysis of the children born after PGD, as a preliminary study for the long-term child Table VIIa . Evolution of pregnancy, data I-V FISH, fluorescent in-situ hybridization; TOP, termination of pregnancy. 1 Subclinical pregnancy defined as pregnancy without any other clinical signs but positive serum hCG. 2 One triplet: fetal reduction, followed by amniocentesis and loss of remaining twin at 16 weeks (one fetal sac counted in reduction, two in miscarriage, one second trimester pregnancy loss after miscarriage counted). 3 One misdiagnosis for sexing, FISH, female fetus, indication social sexing; one misdiagnosis for beta thalassaemia, PCR; one misdiagnosis for myotonic dystrophy, PCR, one misdiagnosis after PGS, karyotype 45,X. 4 TOP for abnormalities found after amniocentesis, not related to the PGD: trisomy 18, indication for PGD parent carrier of reciprocal translocation not involving chromosome 18; one polymalformation, one cystic hygroma, failed karyotype, one Turner mosaic. 5 One misdiagnosis for sexing, PCR, indication Duchenne, twin pregnancy, selective termination of male fetus. Cycle done in 1996, Y-specific amplification only. 6 One fetal sac was tested by FISH and PCR. 7 Number of fetal heart beats not known. Counted further as 1 fetal heart beat. 8 One miscarriage after amniocentesisis. 9 One heterotrophic gestation continued as singleton after reduction of extrauterine gestation at 6 weeks. Vaginal  174  156  18  0  Caesarean  177  119  56  2  Vaginal and Caesarean  2  2  0  0  Unknown  20  18  2  0  Term at delivery  Preterm  105  48  55  2  Term  233  217  16  0  Unknown  35  30  5  0 follow-up. With these measures, ESHRE hopes to help IVF and genetic centres to bring PGD up to today's standards of good laboratory and clinical practice.
Number of pregnancies
Supplementary materials
Supplementary data are available at http:// humrep.oxfordjournals. org/. Table IIc . Chromosomal abnormalities analysed, data VI. 
